|1.||Majumdar, T K: 1 article (01/2000)|
|2.||Tse, F L: 1 article (01/2000)|
|3.||Melamed, D: 1 article (01/2000)|
|4.||Bakhtiar, R: 1 article (01/2000)|
|1.||Asthma (Bronchial Asthma)
05/01/1998 - "In a double-blind, placebo-controlled trial in 16 patients with mild to moderate asthma, a single 1.5 mg inhaled dose of iralukast reduced the incidence of exercise-induced bronchiospasm and was well-tolerated . "
01/01/2000 - "Nonetheless, plasma concentration-time profiles for patients with moderate asthma after oral administration of 200, 500, 1000, and 5000 microgram/kg/day of iralukast were successfully obtained."
05/01/1998 - "Iralukast is an LTD4 and LTE4 antagonist under development by Novartis and in phase II clinical trials as a potential treatment for asthma , . "
01/01/2000 - "Iralukast (CGP 45715A) is a potent peptido-leukotriene antagonist that is active in various in vitro and animal models for the treatment of asthma. "